HighTower Advisors’s DiaMedica Therapeutics DMAC Stock Holding History
Bought
Maintained
Sold
Other funds holding DMAC
HighTower Advisors's DMAC Position: Q3 2026 in Review
HighTower Advisors reduced its DiaMedica Therapeutics (DMAC) stake by 0.44% in Q3 2026, selling an estimated $524 and leaving 17,000 shares worth $141K. The position accounts for ﹤0.01% of the portfolio, ranked #3631.
HighTower Advisors first reported a position in DMAC in Q1 2026 and has held it in 3 quarters since. 73 funds tracked by Wall St. Rank hold DMAC as of Q3 2026.
- HighTower Advisors held 17,000 shares of DiaMedica Therapeutics worth $141K as of Q3 2026.
- HighTower Advisors sold 75 DiaMedica Therapeutics shares in Q3 2026, an estimated $524.
- DiaMedica Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #3631 holding.
- HighTower Advisors first reported a position in DiaMedica Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 73 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2026.
Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.